The “Normal” FVIII Level Trap in Females with Haemophilia
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”The “Normal” FVIII Level Trap in Females with Haemophilia
For decades, we thought: if factors are normal, the patient is “just a carrier” and shouldn’t bleed. At ASH2025, Dr. Jill Johnsen and the 8CHECK program, with over 500 female,s just shattered that rule with data:
- 52% of genotype-positive females with excessive bleeding had FVIII levels ≥ 40%.
- Normal FVIII levels do NOT exclude excessive bleeding.
What This Means for Clinical Practice:
– FVIII is a poor predictor: High variability makes it an unreliable standalone marker for variant status in females.
– Genotyping is essential: It’s not just for “severe” cases. In this cohort, 62% of tested females had a clinically reportable F8 variant.
– Family History Matters: The yield for finding a variant drops significantly without family history (18.6% vs 67.5%), but positive results still occur.”
Stay updated with Hemostasis Today.
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals
-
Dec 18, 2025, 15:12Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
-
Dec 18, 2025, 14:15Plasma-Derived Therapy for Hemophilia in The Updated European Medicines Agency’s Union List
-
Dec 18, 2025, 13:55Laurent Bertoletti: BAT-VTE is One of 7 Projects Funded Under the EFFECT Trial Call!